Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
CORONA

Corona Remedies Share Price

 

 

Corona Remedies live price: ₹1633.4. It opened at ₹1,660 vs previous close ₹1,645; intraday high/low: ₹1,674/₹1,623. The 50 DMA stands at ₹1,562.34.

Corona Remedies Performance

  • Today's Low
  • ₹1,623
  • Today's High
  • ₹1,674
  • 52 Week Low
  • ₹1,337
  • 52 Week High
  • ₹1,724
  • Open Price₹1,660
  • Previous Close₹1,645
  • Volume13,536
  • 50 DMA₹1,562.34
  • 100 DMA-
  • 200 DMA-

Corona Remedies Chart

Investment Returns

  • Over 1 Month + 3.86%
  • Over 3 Month + 16.27%
  • Over 6 Month + 53.8%
  • Over 1 Year + 53.8%

Smart Investing Starts Here Start SIP with Corona Remedies for Steady Growth!

Invest Now

Corona Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 9,990
  • P/B Ratio
  • 14.3
  • Average True Range
  • 76.92
  • EPS
  • 30.17
  • Dividend Yield
  • 0
  • MACD Signal
  • 11.58
  • RSI
  • 55.94
  • MFI
  • 66.85

Corona Remedies Financials

Corona Remedies Technicals

EMA & SMA

Current Price
₹1,633.40
-11.1 (-0.67%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 10
  • 20 Day
  • ₹1,597.66
  • 50 Day
  • ₹1,562.34
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1643.57 Pivot Speed
  • R3 1,715.43
  • R2 1,694.87
  • R1 1,664.13
  • S1 1,612.83
  • S2 1,592.27
  • S3 1,561.53

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Corona Remedies Limited is a fast-growing Indian pharmaceutical company focused on women’s healthcare, cardio-diabeto, pain management, and urology. It operates two manufacturing facilities in Gujarat and Himachal Pradesh with 11 production lines and EU-GMP/WHO-GMP certifications.

Corona Remedies Ltd has an operating revenue of Rs. 2,246.51 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 17% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 8% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Corona Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-02 Quarterly Results
2026-01-02 Quarterly Results Inter-alia, to consider and approve the financial results for the period ended September 30, 2025

Corona Remedies F&O

Corona Remedies Shareholding Pattern

69%
6.35%
0.58%
2.25%
0%
0.77%
21.05%

Corona Remedies FAQs

Corona Remedies share price is ₹1,633 As on 25 April, 2026 | 22:22

The Market Cap of Corona Remedies is ₹9989.9 Cr As on 25 April, 2026 | 22:22

The P/E ratio of Corona Remedies is As on 25 April, 2026 | 22:22

The PB ratio of Corona Remedies is 14.3 As on 25 April, 2026 | 22:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23